• BeOne Medicines (NasdaqGS:ONC) received U.S. FDA Priority Review for BRUKINSA plus rituximab in first-line mantle cell lymphoma.
• The chemotherapy free regimen is based on a pivotal Phase 3 trial that reported reduced risk of disease progression or death versus standard chemoimmunotherapy.
• BeOne Medicines plans to present full Phase 3 data at a major upcoming medical conference and has filed related submissions in Europe and China.
• The BRUKINSA and rituximab Priority Review is one chapter in a broader BeOne Medicines oncology story that investors may want to understand. We have also spotted 3 other big wins worth knowing about at BeOne Medicines.

This move into chemotherapy free lymphoma treatment is one piece of a wider shift in…